GH Research PLC Dossier - Source-backed chat

GH Research PLC

GHRSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.19

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $22.86Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.6B

Enterprise Value $1.3B

Shares Outstanding 61M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

GH Research PLC is a clinical-stage biopharmaceutical company uniquely positioned to disrupt the treatment-resistant depression (TRD) market. Its lead candidate, GH001 (an inhalable formulation of 5-MeO-DMT/mebufotenin), offers an ultra-rapid, highly durable therapeutic effect with a treatment session of approximately 20 minutes. This short duration represents a massive structural advantage over competitors like Compass Pathways (COMP360 psilocybin), which require 6-to-8-hour supervised sessions, significantly lowering delivery costs and increasing patient throughput. Backed by a robust cash position of $267.3 million (pre-April 2026 offering proceeds of $111.2 million) and positive Phase 2b data showing a 73% remission rate at 6 months, GH Research is well-funded to advance its global Phase 3 program targeted for late 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$38.00

Mean target$42.89

High · most bullish analyst$65.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$38.0020%

Regulatory hurdles or requests for additional toxicology/device data from the FDA delay the initiation of the Phase 3 program beyond 2026. Clinical trials experience slow patient enrollment or fail to replicate the high remission rates observed in Phase 2b. Increased R&D burn rates shorten the cash runway, forcing dilutive equity raises before commercialization.

Base CaseCentral scenario

$42.8950%

Matches the consensus mean

GH Research successfully aligns with the FDA and initiates its global Phase 3 program for GH001 in TRD by late 2026 or early 2027. The trials demonstrate robust efficacy and safety, though enrollment timelines proceed at a standard pace. The company's strong cash runway supports operations through Phase 3 readouts. GH002 (intravenous) advances into Phase 2 trials, establishing a diversified pipeline of mebufotenin therapies.

Bull CaseUpside scenario

$65.0030%

The FDA aligns swiftly on the Phase 3 trial design, and the global pivotal program initiates in late 2026 without delays. Phase 3 results replicate the strong Phase 2b efficacy (placebo-adjusted MADRS reduction of -15.5 points) and safety profiles. The proprietary aerosol delivery device is successfully validated, securing a strong IP moat. Commercial adoption is rapid due to the ultra-short 20-minute clinic stay, allowing GH Research to capture dominant market share in TRD and expand into postpartum depression and bipolar II disorder.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Ultra-rapid treatment duration (~20 minutes) compared to 6-8 hours for psilocybin competitors, offering superior clinic economics and patient convenience.
Strong clinical efficacy with Phase 2b trial meeting its primary endpoint (-15.5 placebo-adjusted MADRS reduction) and showing a 73% remission rate at 6 months in the open-label extension.
Excellent safety profile with no treatment-related serious adverse events, suicidal ideation, or behavior reported during the 6-month trial duration.
Robust balance sheet with $267.3 million in cash as of Q1 2026, further bolstered by $111.2 million in net proceeds from an underwritten offering in April 2026, providing an exceptionally long runway.

Key Investment Risks

Binary clinical trial risk associated with the upcoming global Phase 3 pivotal program for GH001.
Regulatory risks, including potential delays in FDA alignment on Phase 3 trial design or clinical holds related to the aerosol delivery device.
Dependence on a single primary asset class (mebufotenin/5-MeO-DMT) across the pipeline.
Commercial execution risks, including the need to build out specialized clinical infrastructure or secure reimbursement for psychedelic-assisted therapies.

Thesis Invalidation Triggers

Failure to obtain FDA alignment or clearance to initiate the Phase 3 pivotal program for GH001 in TRD.
Phase 3 clinical data failing to meet the primary endpoint of statistically significant MADRS reduction compared to placebo.
Emergence of serious, treatment-related adverse events (e.g., severe cardiovascular events or persistent psychosis) in larger patient cohorts.
Severe clinical holds or regulatory rejections of the proprietary aerosol inhalation device.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.